{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-23-000056","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.359226+00:00","generated_at":"2026-06-08T19:06:24.502213+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Halozyme Q3 royalty revenue up 15% to $114.4M; raises 2023 EBITDA & EPS guidance","bullets":["GAAP diluted EPS $0.61, non-GAAP $0.75; royalty revenue $114.4M (+15% YoY).","Total revenue $216M (+3% YoY); operating income $88.3M vs $83.3M.","Accelerates remaining $250M share repurchase into 2023 via ASR (immediate).","Raises 2023 EBITDA guidance to $430-445M, non-GAAP EPS to $2.70-2.80.","Partner milestones: positive CheckMate-67T, Phesgo Japan approval, Tecentriq SC US launch delay to 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-23-000056","json":"https://secwatch.observer/filing/0001159036-23-000056.json","markdown":"https://secwatch.observer/filing/0001159036-23-000056.md","text":"https://secwatch.observer/filing/0001159036-23-000056.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000056/0001159036-23-000056-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000056/halo-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:06:24.502213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e12191c9fc154ce7850611e1a8b9eaadd2667b2","claim":"HALOZYME THERAPEUTICS, INC. reported third quarter ended September 30, 2023 results: revenue $216.0 million, EPS $0.61. Guidance raised.","evidence_excerpt":"endpoints in patients with relapsing forms of multiple sclerosis (“MS”) or primary progressive MS (“RMS” or “PPMS”). Third Quarter 2023 Financial Highlights: • Revenue was $216.0 million compared to $209.0 million in the third quarter of 2022. The 3% year-over-year increase was driven by growth in ENHANZE ® revenue streams with an increase in royalty revenue and","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1159036/000115903623000056/0001159036-23-000056-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$216.0 million"},{"label":"EPS","value":"$0.61"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}